These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 16550610

  • 1. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
    Premkumar DR, Arnold B, Pollack IF.
    Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
    Premkumar DR, Arnold B, Jane EP, Pollack IF.
    Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
    [Abstract] [Full Text] [Related]

  • 3. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 4. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 5. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
    Chang GC, Hsu SL, Tsai JR, Liang FP, Lin SY, Sheu GT, Chen CY.
    Biochem Pharmacol; 2004 Oct 01; 68(7):1453-64. PubMed ID: 15345335
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 7. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T.
    FEBS Lett; 2005 Aug 01; 579(19):4069-75. PubMed ID: 16023108
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L.
    J Cell Physiol; 2004 Feb 01; 198(2):259-68. PubMed ID: 14603528
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 01; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 13. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A.
    J Cell Physiol; 2003 Apr 01; 195(1):139-50. PubMed ID: 12599217
    [Abstract] [Full Text] [Related]

  • 14. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K.
    Cancer Res; 2004 May 15; 64(10):3645-52. PubMed ID: 15150124
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 16. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
    Zanchi C, Zuco V, Lanzi C, Supino R, Zunino F.
    Cancer Res; 2005 Mar 15; 65(6):2364-72. PubMed ID: 15781651
    [Abstract] [Full Text] [Related]

  • 17. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 18. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 19. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM, Li J, Armstrong EA, Harari PM.
    Cancer Res; 2002 Aug 01; 62(15):4300-6. PubMed ID: 12154033
    [Abstract] [Full Text] [Related]

  • 20. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ.
    Cancer Res; 2007 Feb 15; 67(4):1430-5. PubMed ID: 17308080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.